Lv51
1330 积分 2022-04-13 加入
Tolerable Levels of Nonclinical Vehicles and Formulations Used in Studies by Multiple Routes in Multiple Species With Notes on Methods to Improve Utility
11天前
已完结
Elucidating Molecular Mechanisms of Drug-Induced Hepatotoxicity of Lapatinib
1个月前
已完结
Halogenation-Driven Discovery of Halomethylene-Biphenyl-Diarylpyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Improved Safety and PK Profiles
1个月前
已完结
OWL833, an Orally Active Nonpeptide GLP-1 Receptor Agonist, Improves Glucose Tolerance by Increasing Insulin Secretion and Reduces Food Intake of Cynomolgus Monkeys
1个月前
已关闭
Development of a Manufacturing Process for a Key (S)-5-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-1H-indole Intermediate for Orforglipron. Part I. Selection of an Evans Auxiliary-Assisted Asymmetric 1,4-Addition Route
1个月前
已完结
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
1个月前
已完结
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
1个月前
已完结
336-OR: A First-in-Human Single- and Multiple-Ascending Dose Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Nonpeptide GLP-1 Receptor Agonist in Healthy Subjects
1个月前
已关闭
Effect of oral non-peptide GLP-1 receptor agonist orforglipron (LY3502970) in participants with obesity or overweight: A Phase 2 study
1个月前
已完结
Exploring Conformational Transitions in Biased and Balanced Ligand Binding of GLP-1R
1个月前
已完结
皖公网安备34019202002308
